| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
Soyasaponin Ba inhibits human recombinant aldose reductase (hAKR1B1). Its IC50 for L-idose reduction is 40 µM (34–47 µM, 95% confidence limits), and for 4-hydroxynonenal (HNE) reduction is 47 µM (37–59 µM, 95% confidence limits). It acts as a mixed-type inhibitor with dissociation constants Ki = 66 µM and K’i = 24 µM for L-idose, and Ki = 65 µM and K’i = 23 µM for HNE. [1]
|
|---|---|
| ln Vitro |
Soyasaponin Ba (SSBa) inhibited the reduction of both L-idose and HNE catalyzed by purified human recombinant aldose reductase (hAKR1B1) with similar effectiveness, indicating it functions as a conventional aldose reductase inhibitor (ARI) rather than a differential inhibitor (ARDI). [1]
Kinetic analysis revealed that Soyasaponin Ba acts as a mixed-type inhibitor against hAKR1B1 for both substrates (L-idose and HNE), with comparable inhibition constants for each. [1] |
| Enzyme Assay |
The aldose reductase (hAKR1B1) activity was determined spectrophotometrically at 37°C by monitoring the decrease in absorbance at 340 nm due to NADPH oxidation. The standard assay mixture contained sodium phosphate buffer (pH 6.8), NADPH, ammonium sulfate, EDTA, and glyceraldehyde (GAL) as the substrate. For inhibitor testing, L-idose or HNE were used as substrates at specified concentrations instead of GAL. One unit of enzyme activity was defined as the amount catalyzing the conversion of 1 µmol of substrate per minute under the assay conditions. [1]
To evaluate the inhibitory activity of fractions or pure compounds, 8 mU of hAKR1B1 was incubated with the inhibitor and either 0.8 mM L-idose or 0.04 mM HNE as substrates. The percentage inhibition was calculated, and differential inhibition (DI) was defined as the difference between the percentage inhibition observed using L-idose versus HNE as substrates. [1] For detailed kinetic characterization (e.g., determination of IC50, Ki, K’i), the activity of the purified enzyme was measured at varying concentrations of the substrate (L-idose or HNE) in the absence and presence of different concentrations of the inhibitor (Soyasaponin Ba or Soyasaponin Bb). Data were analyzed using Hanes-Woolf plots and secondary plots to determine the mode of inhibition and inhibition constants. [1] |
| References | |
| Additional Infomation |
(2S,3S,4S,5R,6R)-6-[[(3S,4S,4aR,6aR,6bS,8aR,9R,12aS,14aR,14bR)-9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecanoic acid has been reported in soybean (Glycine max) and lotus root (Lotus oleracea). En-3-yl]oxy]-5-[(2S,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxetane-2-yl]oxyoxetane-2-yl]oxy-3,4-dihydroxyoxetane-2-carboxylic acid.
Soy saponin Ba is a triterpenoid saponin that was identified from the methanol extract of the seeds of the local cultivar of Zolfino soybean (Phaseolus vulgaris L.). [1] This study highlights the challenge of identifying differential inhibitors of aldose reductase (ARDI) in complex mixtures, as the presence of conventionally potent inhibitors like soybean saponin Ba can mask the differential inhibitory effects of other components. [1] The inhibitory effect of soybean saponin Ba is not dependent on the nature of the substrate (sugar or aldehyde), unlike some other saponins that exhibit differential inhibitory effects (e.g., soybean saponin Bb). [1] |
| Molecular Formula |
C48H78O19
|
|---|---|
| Molecular Weight |
959.1215
|
| Exact Mass |
958.513
|
| CAS # |
114590-20-4
|
| PubChem CID |
91973815
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
1054.6±65.0 °C at 760 mmHg
|
| Flash Point |
300.1±27.8 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.631
|
| LogP |
5.85
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
67
|
| Complexity |
1840
|
| Defined Atom Stereocenter Count |
25
|
| SMILES |
C[C@]12CC[C@@H]([C@]([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(C[C@H]5O)(C)C)C)C)C)(C)CO)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O
|
| InChi Key |
WFRQIKSNAYYUJZ-BKQVBUAGSA-N
|
| InChi Code |
InChI=1S/C48H78O19/c1-43(2)16-22-21-8-9-26-45(4)12-11-28(46(5,20-51)25(45)10-13-48(26,7)47(21,6)15-14-44(22,3)27(52)17-43)64-42-38(34(58)33(57)36(65-42)39(60)61)67-41-37(32(56)30(54)24(19-50)63-41)66-40-35(59)31(55)29(53)23(18-49)62-40/h8,22-38,40-42,49-59H,9-20H2,1-7H3,(H,60,61)/t22-,23+,24+,25+,26+,27+,28-,29+,30-,31-,32-,33-,34-,35+,36-,37+,38+,40-,41-,42+,44+,45-,46+,47+,48+/m0/s1
|
| Chemical Name |
(2S,3S,4S,5R,6R)-6-[[(3S,4S,4aR,6aR,6bS,8aR,9R,12aS,14aR,14bR)-9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-5-[(2S,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxyoxane-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~260.66 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0426 mL | 5.2131 mL | 10.4262 mL | |
| 5 mM | 0.2085 mL | 1.0426 mL | 2.0852 mL | |
| 10 mM | 0.1043 mL | 0.5213 mL | 1.0426 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
